USRE37872E1 - Storage of materials - Google Patents
Storage of materials Download PDFInfo
- Publication number
- USRE37872E1 USRE37872E1 US09/270,791 US27079199A USRE37872E US RE37872 E1 USRE37872 E1 US RE37872E1 US 27079199 A US27079199 A US 27079199A US RE37872 E USRE37872 E US RE37872E
- Authority
- US
- United States
- Prior art keywords
- water
- composition
- carrier substance
- nucleosides
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
- C12N11/087—Acrylic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
Definitions
- This invention relates to the stabilisation and storage of materials.
- the principal envisaged field of application is materials employed in the biochemical field and some pharmaceuticals.
- a few biologically active materials e.g. some proteins are sufficiently stable that they can be isolated, purified and then stored in solution at room temperature. For most materials however this is not possible and some more elaborate form of stabilisation/storage procedure must be used.
- cryoprotectant additive present in sufficient concentration (e.g. glycerol) to depress the freezing point to below the storage temperature and so avoid freezing.
- a cryoprotectant additive present in sufficient concentration (e.g. glycerol) to depress the freezing point to below the storage temperature and so avoid freezing.
- glycerol e.g. glycerol
- the enzymes need to be protected against freezing by the addition of high concentrations of glycerol and maintained at ⁇ 20° C.
- Use of an additive in high concentration may also reduce the specificity of restriction enzymes and give rise to so-called “star-activity”. (B. Polisky et al. PNAS USA. 72, 3310 (1975)).
- the commonest method for the stabilization of isolated protein preparations is freeze-drying, but this process can only be applied to freeze-stable products.
- the aqueous isolate of the active material in a suitable pH buffer and in the presence of a cryoprotectant is first frozen, typically to ⁇ 40° to ⁇ 50° C.; the ice is then removed by sublimation under vacuum and at low sub-zero temperatures, following which the residual moisture which may amount up to 50% of the “dried” preparation is removed by desorption during which the temperature gradually rises.
- the complete freeze-drying cycle may take several days and is costly in capital and energy. Freeze-drying also suffers from technical disadvantages because of its irreproducibility. Suppliers of freeze-dried protein products generally specify storage at ⁇ 20° C. rather than ambient temperature. Exposure to ambient temperatures for periods of days to weeks can result in significant activity losses.
- this invention provides a storable composition
- a storable composition comprising at least one material to be stored, preferably selected from the group consisting of proteins, peptides, nucleosides, nucleotides and enzyme cofactors, dissolved in a water-soluble or water-swellable substance which is in an amorphous, glassy or (much less preferably) rubbery state.
- the composition displays a glass transition temperature of at least 20° C. preferably at least 30° C.
- the composition has a water content of not more than 4% by weight.
- the invention may be utilised for stable storage of a single material, or for a mixture of materials which have little or no effect on each other.
- a single composition contains a plurality of materials which form part or all of a reacting system. These may be fairly simple chemicals.
- this invention provides a method of rendering a material suitable for storage, comprising dissolving the material in a water-soluble or water-swellable substance or solution thereof and forming the resulting mixture into a glass.
- This process is capable of being carried out without the use of any non-aqueous organic solvent, which is advantageous because such solvent could prove harmful to many substances. Also processing with and/or removal of organic solvents can be undesirable for environmental reasons.
- the material(s) stabilized for storage may potentially be any of a wide range of materials which are ordinarily liable to undergo a chemical reaction which is dependent on diffusion of reacting species.
- proteins and peptides including derivatives thereof such as glycoproteins.
- proteins and peptides may be any of: enzymes, transport proteins, e.g. haemoglobin, immunoglobulins, hormones, blood clotting factors and pharmacologically active proteins or peptides.
- nucleosides nucleotides, dinucleotides, oligonucleotides (say containing up to four nucleotides) and also enzyme cofactors, whether or not these are nucleotides.
- Enzyme substrates in general are materials to which the invention may be applied.
- the material for stabilisation and storage may be isolated from a natural source, animal, plant, fungal or bacterial, or may be produced by and isolated from cells grown by fermentation in artificial culture. Such cells may or may not be genetically transformed cells.
- the material will need to be soluble in aqueous solution, at least to the extent of forming a dilute solution which can be used for incorporation into the glass forming substance.
- a development of this invention is to store more than one component of a reacting system in a glass. This can be useful for materials which will be required to be used together in, for example, an assay or a diagnostic kit.
- one or more of the materials may be a protein, peptide, nucleoside, nucleotide or enzyme cofactor. It is also possible that the materials may be simpler species. For instance a standard assay procedure may require pyruvate and NADH to be present together. Both can be stored alone with acceptable stability. However, when brought together in aqueous solution they begin to react. If put together in required proportions in the glassy state they do not react and the glass can be stored.
- a glass is defined as an undercooled liquid with a very high viscosity, that is to say at least 10 13 Pa.s, probably 10 14 Pa.s or more.
- a glass presents the appearance of a homogeneous, transparent, brittle solid which can be ground or milled to a powder.
- diffusive processes take place at extremely low rates, such as microns per year. Chemical or biochemical changes including more than one reacting moiety are practically inhibited.
- the glass forming substance employed in this invention must be hydrophilic—either water-soluble or water-swellable—so that water will act as a plasticiser.
- Many hydrophilic materials both of a monomeric and a polymeric nature either exist as or can be converted into amorphous states which exhibit the glass/rubber transitions characteristic of amorphous macromolecule. They have well defined glass transition temperatures T g which depend on the molecular weight and a molecular complexity of the glass forming substance. T g is depressed by the addition of diluents. Water is the universal plasticiser for all such hydrophilic materials. Therefore, the glass/rubber transition temperature is adjustable by the addition of water or an aqueous solution.
- T g of the final composition is sufficiently high, storage can be at room temperature. However, if T g of the composition is close to or below room temperature it may be necessary or desirable to refrigerate the glassy composition if storage is for a prolonged period. This is less convenient but still is more economical than freeze-drying.
- composition If the composition is heated above its T g during storage, it will change to its rubbery state. Even in this condition stored materials are stable for a considerable period of time. Consequently, it may well do no harm if the temperature of the stored material is allowed to go above T g for a limited time, such as during transportation.
- T g of the composition is well above room temperature, the composition is better able to withstand storage at an elevated temperature, e.g. in a hot climate.
- T g of the formulated composition is typically 5° below T g of the anhydrous glass forming substance.
- the glass forming substance should be sufficiently chemically inert towards the material which is to be incorporated in it.
- An absolute absence of chemical reactivity may not be essential, as long as it is possible to incorporate the material, store the glass, and recover the material without serious degradation through chemical reaction.
- polyhydroxy compounds can be used, such as carbohydrate derivates like sorbitol and chemically modified carbohydrates.
- glass forming substances are water-soluble or water-swellable synthetic polymers, such as polyvinyl pyrrolidone, polyacrylamide or polyethyleneimine.
- T g is a function of the molecular weight. Both of these classes of glass forming substances are suitable for the present invention.
- a group of glass forming substances which may in particular be employed are sugar copolymers described in U.S. Pat. No. 3,300,474 and sold by Pharmacia under the Registered Trade Mark “Ficoll”.
- This U.S. patent describes the materials as having molecular weight 5,000 to 1,000,000 and containing sucrose residues linked through ether bridges to bifunctional groups.
- Such groups may be alkylene of 2, 3 or more carbon atoms but not normally more than 10 carbon atoms.
- the bifunctional groups serve to connect sugar residues together.
- These polymers may for example be made by reaction of the sugar with a halohydrin or a bis-epoxy compound.
- One process of rendering a material storage stable in accordance with the present invention commences from an aqueous solution of the material (which will be referred to as the active material), and a supply of the substance into which it is to be incorporated, with this substance already in an amorphous state, either glassy or rubbery.
- the materials are mixed to homogenise the glass forming substance with the active material.
- the rubbery form has the consistency of a dough and can be rolled or milled into a thin sheet. This rubber is then subjected to reduced pressure, possibly accompanied by moderate heat, in order to remove most of the added moisture.
- the final product is a glass with a glass temperature slightly, e.g. approximately 5°, below that of the pure glass forming substance. It can be kept in the form of a transparent film or ground into a fine powder or compressed into tablet form.
- the glass forming substance and the amount of solution added to it are chosen so that the rubbery material obtained from the addition is at a temperature above its T g (or to put it another way, its T g is below the ambient temperature) but as moisture is removed the value of T g increases to above the ambient temperature.
- the starting substance also has its T g above ambient temperature, so that lowering of T g on addition of aqueous solution lowers this value from above ambient to below.
- T g above ambient temperature
- the amount of aqueous solution which can and should be added to form a rubbery dough may well be found by trial and error. It is likely to be not more than 5% by weight based on the glass forming substance.
- the steps of adding solution to form a rubbery dough and drying this back to a glassy state can be repeated to build up the concentration of active material in the glass.
- the T g value of a sample of a glass forming substance can be determined, and determined again after mixing in varying amounts of water, so as to be able to plot a graph of T g against moisture content.
- Vacuum applied to assist the removal of water from the rubbery composition need not be particularly hard. Suitably it is less than 90% of normal atmospheric pressure. A pressure which is 80% of normal atmospheric pressure has been found adequate. A harder vacuum may be employed, however, if this is found convenient.
- Heating of the doughy mixture to remove moisture may be at a temperature not above 80°, and for a protein is preferably not above 60° C. Heating may not be necessary: evaporation of moisture under reduced pressure may proceed to a sufficiently low moisture content even at room temperature of around 20° C., but of course heat accelerates the evaporation.
- Another process for rendering material storage stable in accordance with the present invention can enable the material to be stored and recovered at a greater concentration of active material relative to the carrier substance.
- a quantity of the carrier substance, or a solution thereof is added to a solution of the active material.
- the solution may be divided into convenient portions, e.g. 0.1 to 1 ml.
- the samples of solution are placed under reduced pressure so that water is evaporated from them until the carrier substance is in a glassy state. Typical conditions are to commence the evaporation at a temperature not exceeding 40° C., preferably in the range from 20 to 30° C. and continue it for some hours, for instance 24 to 36 hours. As evaporation continues the glass temperature of the residual material rises.
- Evaporation for the period indicated can be sufficient to achieve a glass transition temperature exceeding 30° C.
- the temperature may be raised while evaporation continues. For instance once the glass transition temperature has reached a level of 30° C. the temperature may be raised to within a range of 40 to 70° C., e.g. 60° C. for a shorter time such as two hours.
- vacuum used to bring about evaporation of water does not need to be particularly hard. It may also be found that heating is unnecessary: evaporation without heating for an extended time may achieve a sufficiently low moisture content.
- the carrier substance may be added in a dry state, e.g. a powder, or as a solution.
- the suitability of an intended glass forming substance and conditions for incorporation of material into it can both be checked by preparing a glass with the material incorporated, and then recovering the material without any substantial period of storage.
- Storage stability can, if desired, be tested by storage at a higher temperature such as 35° C. or even 50° C. which gives an accelerated test.
- material is stored at a temperature above ambient, to provide an accelerated test of storage life.
- Examples 1 and 2 describe the storage of lactate dehydrogenase (LDH) which is assayed using a combination of NADH and pyruvate.
- Example 4 shows the storage of the unstable mixture of NADH with pyruvate. This would provide a suitable material for use in carrying out LDH assays, but in Example 4 that assay procedure is used to confirm the activity of the NADH/pyruvate after storage.
- LDH lactate dehydrogenase
- Example 3 describes storage of restriction enzyme, and the activity of the stored enzyme is confirmed by showing that its effect on DNA remains unchanged.
- the glass forming substance employed was Ficoll 400 DL (Pharmacia, Reg. Trade Mark) which is a copolymer of sucrose and epichlorohydrin. It is water-soluble and has a T g of 97° C. 4 grams of the Ficoll was weighed (w e ) into a dry Universal tube. About 50% was placed into a dry mortar and 0.2 ml of a solution containing 1,000 units/ml lactate dehydrogenase LDH (ex rabbit muscle) in 0.01M phosphate buffer pH 7.0 was added and mixed well into the Ficoll. A further 0.2 ml of LDH solution was then incorporated into the mix. A small amount of Ficoll was added, until a dough was obtained which did not adhere to the pestle.
- Ficoll 400 DL Pharmacia, Reg. Trade Mark
- the dough was rolled out on a tile to give a sheet of approx 1 mm thickness. It was separated from the tile with a knife and lightly replaced onto the tile which was then heated in an oven for 30 minutes at 45-50° C. The sheet was removed from the oven and ground to a fine free-flowing powder which was stored in a sealed tube. The unused Ficoll was weighed (w e ). The powder containing the LDH was stored in the laboratory where temperatures fluctuated between 20 and 35° C.
- LDH ⁇ ⁇ activity ⁇ ⁇ ( units/grams ) approx ⁇ ⁇ 0.4 ⁇ ⁇ I ( w s - w c )
- I is the initial concentration of LD in the solution in units/ml.
- the actual LDH activity of the powder was assayed. On the assumption that the powder contained negligible moisture, the powder was dissolved in phosphate buffer (0.01M pH 7) to give a test solution calculated to be a 1 to 1,000 dilution of the original solution. This would contain 1 unit of LDH per ml if enzyme activity was entirely preserved. Its actual activity was determined by the following procedure (Hatley, Franks and Mathias, Process Biochemistry, December 1987 page 170).
- ⁇ A the absorbance change per minute at 340 nm.
- 6.25 a correction factor for the molar absorbance of NADH.
- TCF a temperature correction factor which must be applied for assays performed at temperatures other than 25° C.
- the stability of the product was compared to that of a commercial LDH preparation in 2.1M ammonium sulphate (Type II, 10,000 units/ml ex Sigma) which was stored at 25° C. and assayed periodically by the above method.
- the activity of this commercial preparation decreased on average by 1.2% per day over the first 45 days.
- a quantity of crystalline sucrose was gently heated to melting on a hotplate under a dry, oxygen-free atmosphere. (Dry nitrogen was used). The sucrose was allowed to cool to give a transparent glass and was then ground into a fine powder, still under a dry atmosphere, and stored in a stoppered tube. 0.4 ml of an LDH solution, containing 4,000 units/ml, in 0.01M phosphate buffer pH 7.0 was added to 4 g of the sucrose glass and mixed using a pestle and mortar. The resulting paste was rolled out on a tile into a thin sheet which was then freed from, and lightly replaced on the tile. It was next heated in an oven for 30 minutes at 40-50° C. after which it was allowed to cool.
- I is the initial LDH activity (units/ml) in the solution used to prepare the glass.
- the preparation was assayed periodically for LDH activity, as described in Example 1. No loss of activity could be detected after 1 month storage at 25° C.
- the glass temperature of the preparation was determined by differential scanning calorimetry as 32° C.
- An assay for enzyme activity was carried out by the following procedure (which is taken from LKB Laboratory Manual: LKB 2013 Miniphor Submarine Electrophoresis Unit 1985, Chapter 6). The solution was incubated with 1 ⁇ g lamda-DNA for 1 hour at 37° C. Electrophoresis of the incubation mixture was then carried out on Q.5% agarose gel in Tris/borate buffer in standard manner. The DNA breakdown bands observed on the gel corresponded exactly with those of a control run with a fresh enzyme solution.
- a solution containing 100 mg/ml NADH and 33 mg/ml pyruvate was prepared. 0.4 ml of this solution were incorporated into 4 g of a sucrose glass and the mixture processed, as described in Example 2.
- the mixed glass was stored in 20 mg quantities in spectrophotometer cuvettes which were closed with sealing film and kept in a laboratory where the temperature fluctuated between 20 and 35° C. The glass was stored for 14 days.
- the contents of a cuvette were dissolved in 2.7ml of 0.01M phosphate buffer (pH 7.0) and 0.1 ml of a LDH solution containing 1 unit/ml was added.
- the absorbance at 340 nm was recorded at 30 second intervals for a total period of 3 minutes and the temperature of the solution was measured.
- the apparent LDH enzyme activity was determined from the period during which the absorbance change was linear with time. The activity was calculated as in Example 1.
- a control assay was carried out with fresh solutions of NADH and pyruvate. The apparent activity obtained using the dissolved glass closely matched the control value.
- Vials were periodically rehydrated by adding 2.23 ml of 50 mM Tris/HCl buffer at pH 7.5, containing 0.3 mM EDTA to give a solution which, assuming no loss of activity, would have contained 100 units of enzyme per ml. This was serially diluted to 1 unit/ml in the same buffer. The actual activity of the recovered enzyme was determined.
- the assay procedure for recovered enzyme made use of the following solutions:
- Assay was carried out using a standard assay procedure published by Boeringer Mannheim. The assay monitors the decrease in absorbance at 245 nm as the enzyme catalyses the oxidation of a known solution of ascorbic acid. Enzyme which had been stored for 2 months at 35° C. was found, within the limits of experimental error, to have the same activity as enzyme which was stored for only a very short time.
- Lactate dehydrogenase was incorporated into Ficoll 400 using the procedure of Example 5.
- the Ficoll:enzyme ratio was 0.23:0.26.
- Samples were stored for various periods and then recovered by adding 0.01M phosphate buffer in a quantity which would give a theoretical activity of 1 unit/ml, assuming full retention of activity.
- the recovered solutions were assayed using the procedure set out in Example 1.
- the measured activity of recovered material, as a percentage of the theoretical activity was:
- Cytochrome C reductase was incorporated into Ficoll 400 by the procedure of Example 5. The ratio of enzyme:Ficoll was 1:1. Samples were subjected to an accelerated test, viz. stored for 14 days at 35° C., and then recovered by adding 4 ml of 0.2M KHCO 3 to give a solution with a theoretical activity of 0.87 unit/ml assuming full retention of activity. The recovered material was assayed using a procedure given in “Methods in Enzymology” by Mahler, Volume II 1955 p. 688. It was found that the recovered material had an activity of 88% of the theoretical value.
- Glycerol-3-phosphate dehydrogenase was incorporated into Ficoll 400 by the procedure of Examples. The ratio of enzyme:Ficoll was 1:2. Samples were subjected to an accelerated storage test by storage at 35° C. After 7 days storage the material was recovered by adding 0.05M Tris/HCl buffer at pH 7.6. This also contained 2 mg/ml albumin and 0.74 mg/ml EDTA. The recovered material was assayed using a procedure published by Biozyme Laboratories in which the enzyme catalyses the reaction:
- Alpha-glucosidase was incorporated into Ficoll 400 using the procedure of Example 5.
- the Ficoll:enzyme ratio was 1:1.
- samples were stored for various periods at 35° C. and then recovered by adding 4 mls of 0.067M phosphate buffer at pH 7.0 to give a solution whose theoretical activity, assuming full retention of activity, was 2 units/ml.
- the recovered solutions were assayed by a procedure described by H. Halvorson, Methods in Enzymology 8 559 (1966). The actual activity of recovered material relative to the theoretical value was:
- NADH 5 g of Ficoll 400 was added to 20 ml of a 2 mg/ml NADH solution. This was divided into 40 portions, each containing 0.25 ml, and processed as in Example 5 to give glasses.
- NADH and pyruvate were processed as in Example 11. Portions of each resulting glass powder were mixed together. One such mixture was at once rehydrated and assayed by the procedure of Example 4.
- the reaction mixture consisted of 2.8 mls 0.01M phosphate buffer, 0.1 ml of rehydrated NADH/pyruvate mixture, and 0.1 mls of 1 unit/ml enzyme solution. The change in absorbance at 340 nm over three minutes was defined as 100%.
- a range of carrier materials were used in a standard procedure in which the stored active material is lactate dehydrogenase.
- a solution consisting of 0.05 g of carrier dissolved in 100 ml 0.01M phosphate buffer was prepared. 1 ml of 10 mg/ml lactate dehydrogenase solution was then added to 20 ml of the prepared solution. The solution thus created was divided into 0.5 ml aliquots in glass vials. These were dried under reduced pressure of about 80% atmospheric in a vacuum oven at 36° C. for 24 hours. After drying the vials were sealed and stored at ambient temperature. The product had a carrier:protein ratio by weight of 1:0.22.
Abstract
Description
Process | Storage | Initial | Duration of Storage (weeks) |
Temperature | Temperature | Activity | 1 | 2 | 3 | 4 | 6 | 12 |
37° C. | ambient | 97% | 95% | 99% | 98% | 86% | ||
37° C. | 35° C. | 97% | 78% | 82% | 87% | 84% | ||
37° C. | 25° C. | 130% | 122% | 121% | 83% | 69% | 74% | |
60° C. | ambient | 103% | 109% | 96% | 85% | 98% | 97% | |
60° C. | 35° C. | 103% | 102% | 105% | 96% | 116% | ||
60° C. | 25° C. | 121% | 114% | 125% | 84% | 81% | 89% | |
Freeze- | 25° C. | 56% | 40% | 35% | 33% | 36% | ||
dried | ||||||||
Before | Storage period (days) |
Drying | 1 | 14 | 21 | 28 | 35 | 180 |
100% | 91% | 81% | 91% | 112% | 97% | 98% |
Before | Storage period (days at 35° C.) |
Drying | 1 | 4 | 11 | 90 |
100% | 100% | 103% | 95% | 70% |
Storage period at 25° C. (weeks) |
Carrier | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 10 | 12 | 16 |
Maltorrione | 100 | 114 | 91 | 96 | 68 | 71 | 101 | 94 | ||
Polydestrone | 100 | 132 | 123 | 103 | 116 | 146 | 103 | |||
Inulin | 100 | 99 | 91 | 95 | 114 | 98 | 91 | |||
Stachyose | 100 | 122 | 137 | 140 | 109 | 106 | 127 | |||
Dextran | 100 | 81 | 71 | 89 | 102 | 91 | 95 | 84 | ||
Sorbose | 100 | 93 | 75 | 76 | 55 | 66 | 65 | 58 | 62 | |
Polyacrylamide | 100 | 100 | 80 | 71 | 53 | 62 | 55 | 63 | ||
PVP | 100 | 75 | 76 | 70 | 62 | |||||
GPS | 100 | 124 | ||||||||
Palatinit | 100 | 99 | ||||||||
Claims (110)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/270,791 USRE37872E1 (en) | 1989-02-16 | 1999-03-17 | Storage of materials |
US09/939,688 USRE38385E1 (en) | 1989-02-16 | 2001-08-28 | Storage of materials |
US09/939,689 USRE39497E1 (en) | 1989-02-16 | 2001-08-28 | Storage of materials |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898903593A GB8903593D0 (en) | 1989-02-16 | 1989-02-16 | Storage of materials |
GB8903593 | 1989-02-16 | ||
US07/479,939 US5098893A (en) | 1989-02-16 | 1990-02-12 | Storage of materials |
US09/270,791 USRE37872E1 (en) | 1989-02-16 | 1999-03-17 | Storage of materials |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/479,939 Reissue US5098893A (en) | 1989-02-16 | 1990-02-12 | Storage of materials |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/479,939 Continuation US5098893A (en) | 1989-02-16 | 1990-02-12 | Storage of materials |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE37872E1 true USRE37872E1 (en) | 2002-10-08 |
Family
ID=10651841
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/479,939 Ceased US5098893A (en) | 1989-02-16 | 1990-02-12 | Storage of materials |
US09/270,791 Expired - Lifetime USRE37872E1 (en) | 1989-02-16 | 1999-03-17 | Storage of materials |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/479,939 Ceased US5098893A (en) | 1989-02-16 | 1990-02-12 | Storage of materials |
Country Status (8)
Country | Link |
---|---|
US (2) | US5098893A (en) |
EP (1) | EP0383569B1 (en) |
JP (1) | JP3068836B2 (en) |
AU (1) | AU622978B2 (en) |
CA (1) | CA2010058C (en) |
DE (1) | DE69008891T2 (en) |
DK (1) | DK0383569T3 (en) |
GB (1) | GB8903593D0 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE38385E1 (en) * | 1989-02-16 | 2004-01-13 | Nektar Therapeutics | Storage of materials |
US20050003004A1 (en) * | 2003-05-28 | 2005-01-06 | Nektar Therapeutics | Pharmaceutical formulation comprising a water-insoluble active agent |
US20050048127A1 (en) * | 2003-07-22 | 2005-03-03 | Larry Brown | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
US20050142201A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for fabrication, uses and compositions of small spherical particles of hGH prepared by controlled phase separation |
US20050170005A1 (en) * | 2003-07-18 | 2005-08-04 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
US20060018971A1 (en) * | 2004-05-12 | 2006-01-26 | Terrence Scott | Nucleic acid microspheres, production and delivery thereof |
US20060024379A1 (en) * | 2004-05-12 | 2006-02-02 | Larry Brown | Protein microspheres having injectable properties at high concentrations |
US20060039985A1 (en) * | 2004-04-27 | 2006-02-23 | Bennett David B | Methotrexate compositions |
US20100047903A1 (en) * | 2008-08-20 | 2010-02-25 | Baxter International Inc. | Methods of processing compositions containing microparticles |
US7744925B2 (en) | 1994-12-02 | 2010-06-29 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
WO2010138868A2 (en) | 2009-05-29 | 2010-12-02 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems |
US7964574B2 (en) | 2006-08-04 | 2011-06-21 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
US8323615B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing multi-phasic dispersions |
US8324266B2 (en) | 2009-05-29 | 2012-12-04 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
US8367427B2 (en) | 2008-08-20 | 2013-02-05 | Baxter International Inc. | Methods of processing compositions containing microparticles |
US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
WO2014190204A1 (en) | 2013-05-22 | 2014-11-27 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of three or more active agents |
US8900856B2 (en) | 2004-04-08 | 2014-12-02 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
US9115357B2 (en) | 2004-05-12 | 2015-08-25 | Baxter International Inc. | Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US10064404B2 (en) | 2014-06-10 | 2018-09-04 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US10568317B2 (en) | 2015-12-08 | 2020-02-25 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US11286526B2 (en) | 2017-05-19 | 2022-03-29 | Gen-Probe Incorporated | Dried compositions containing flap endonuclease |
US11471468B2 (en) | 2013-03-15 | 2022-10-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
WO2023283441A1 (en) | 2021-07-09 | 2023-01-12 | Astrazeneca Pharmaceuticals Lp | Compositions, methods and systems for aerosol drug delivery |
WO2023119093A1 (en) | 2021-12-20 | 2023-06-29 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery |
WO2023212191A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120643A (en) * | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US5958670A (en) * | 1988-05-18 | 1999-09-28 | Cobe Laboratories, Inc. | Method of freezing cells and cell-like materials |
US5045446A (en) * | 1988-08-26 | 1991-09-03 | Cryopharm Corporation | Lyophilization of cells |
IL90188A0 (en) * | 1988-05-18 | 1989-12-15 | Cryopharm Corp | Process and medium for the lyophilization of erythrocytes |
GB9010742D0 (en) * | 1990-05-14 | 1990-07-04 | Quadrant Bioresources Ltd | Stabilization of biological macromolecular substances |
US5621094A (en) * | 1990-05-14 | 1997-04-15 | Quadrant Holdings Cambridge Limited | Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol |
US5993805A (en) * | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
AU659645B2 (en) * | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
GB9115154D0 (en) * | 1991-07-12 | 1991-08-28 | Patel Bipin C M | Sol-gel composition for producing glassy coatings |
GB9115153D0 (en) * | 1991-07-12 | 1991-08-28 | Patel Bipin C M | Sol-gel composition for producing glassy coatings |
US5250429A (en) * | 1991-09-20 | 1993-10-05 | Pharmacia P-L Biochemicals Inc. | Glassified restriction enzymes |
EP0624190A4 (en) * | 1992-01-21 | 1995-04-19 | Cryopharm Corp | Method of freezing cells and cell-like materials. |
SE9201929D0 (en) * | 1992-06-23 | 1992-06-23 | Pharmacia Lkb Biotech | METHOD AND SYSTEM FOR MOLECULAR-BIOLOGICAL DIAGNOSTICS |
US6673335B1 (en) * | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
US5792505A (en) * | 1992-09-22 | 1998-08-11 | Mccormick & Company, Inc. | Flavor encapsulation |
DK0679088T3 (en) * | 1992-09-29 | 2002-10-28 | Inhale Therapeutic Syst | Pulmonary delivery of active fragments of parathyroid hormone |
US5599660A (en) * | 1993-01-19 | 1997-02-04 | Pharmacia Biotech Inc. | Method and preparation for sequential delivery of wax-embedded, inactivated biological and chemical reagents |
US6024090A (en) * | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
US7448375B2 (en) * | 1993-01-29 | 2008-11-11 | Aradigm Corporation | Method of treating diabetes mellitus in a patient |
JPH08509018A (en) * | 1993-04-16 | 1996-09-24 | マコーミック アンド カンパニー,インク. | Encapsulation composition |
GB9308734D0 (en) * | 1993-04-28 | 1993-06-09 | Ici Plc | Viable bacteria |
JPH07191035A (en) | 1993-11-17 | 1995-07-28 | Toppan Printing Co Ltd | Physiologically active material-immobilized sheet, its manufacture and preservation, and method for supplying physiologically active material using it |
CZ295827B6 (en) * | 1994-03-07 | 2005-11-16 | Nektar Therapeutics | Method for aerosolizing a dose of insulin, insulin composition and use thereof |
US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
EP0759939B1 (en) * | 1994-05-18 | 2005-07-20 | Nektar Therapeutics | Methods and compositions for the dry powder formulation of interferons |
ES2194911T3 (en) * | 1994-06-02 | 2003-12-01 | Elan Drug Delivery Ltd | METHOD FOR AVOIDING PROTEIN / PEPTIDES AGGREGATION WHEN YOUR REHYDRATION OR DEFROSTING IS LOCATED. |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
EP1138319A3 (en) | 1994-08-04 | 2003-03-19 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US5593824A (en) * | 1994-09-02 | 1997-01-14 | Pharmacia Biotech, Inc. | Biological reagent spheres |
US5565318A (en) * | 1994-09-02 | 1996-10-15 | Pharmacia Biotech, Inc. | Room temperature stable reagent semi-spheres |
US6258341B1 (en) * | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
GB9508691D0 (en) * | 1995-04-28 | 1995-06-14 | Pafra Ltd | Stable compositions |
US5756136A (en) * | 1995-06-02 | 1998-05-26 | Mccormick & Company, Inc. | Controlled release encapsulation compositions |
US6964771B1 (en) | 1995-06-07 | 2005-11-15 | Elan Drug Delivery Limited | Method for stably incorporating substances within dry, foamed glass matrices |
MX9702146A (en) * | 1995-07-28 | 1997-06-28 | Gist Brocades Bv | Salt-stabilized enzyme preparations. |
US6274369B1 (en) | 1996-02-02 | 2001-08-14 | Invitrogen Corporation | Method capable of increasing competency of bacterial cell transformation |
WO1997036613A1 (en) | 1996-03-29 | 1997-10-09 | Life Technologies, Inc. | Method for increasing viability and transformation efficiency of bacteria during storage at low temperatures |
US5766520A (en) * | 1996-07-15 | 1998-06-16 | Universal Preservation Technologies, Inc. | Preservation by foam formation |
WO1997045009A2 (en) | 1996-05-29 | 1997-12-04 | Universal Preservation Technologies, Inc. | Long-term shelf preservation by vitrification |
US5876992A (en) * | 1996-07-03 | 1999-03-02 | Molecular Biology Resources, Inc. | Method and formulation for stabilization of enzymes |
GB9619893D0 (en) * | 1996-09-24 | 1996-11-06 | Zeneca Ltd | Novel composition |
WO1998018338A1 (en) | 1996-10-25 | 1998-05-07 | Mccormick & Company, Inc. | Fat-coated encapsulation compositions and method for preparing the same |
FR2755440B1 (en) * | 1996-11-07 | 1999-01-15 | Tuffet Sophie | METHOD FOR THE LONG-TERM PRESERVATION OF DNA MOLECULES AND PACKAGING FOR ITS IMPLEMENTATION |
SE9604795D0 (en) * | 1996-12-20 | 1996-12-20 | Astra Pharma Prod | New pharmaceutical formulation |
US20030203036A1 (en) | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
WO1998035018A1 (en) | 1997-02-12 | 1998-08-13 | Life Technologies, Inc. | Methods for lyophilizing competent cells |
US6989259B2 (en) | 1997-04-22 | 2006-01-24 | Invitrogen Corporation | Recombinant methods for making reverse transcriptases and mutants thereof |
US5972395A (en) * | 1997-04-25 | 1999-10-26 | Kraft Foods, Inc. | Method of preparing glass stabilized material |
IL124275A (en) * | 1997-05-02 | 2002-03-10 | Bio Merieux Vitek Inc | Method for generating nucleic acid sequences |
US6558901B1 (en) * | 1997-05-02 | 2003-05-06 | Biomerieux Vitek | Nucleic acid assays |
US20030035778A1 (en) * | 1997-07-14 | 2003-02-20 | Robert Platz | Methods and compositions for the dry powder formulation of interferon |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
EP0913177A1 (en) * | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Process for producing dry, amorphous products comprising biological active materials by means of convection drying technique, especially spray drying |
EP0913178A1 (en) * | 1997-11-03 | 1999-05-06 | Boehringer Mannheim Gmbh | Process for the manufacture of dry, amorphous products comprising biologically active material by means of convection drying and products obtainable by the process |
WO1999027071A1 (en) * | 1997-11-26 | 1999-06-03 | Universal Preservation Technologies, Inc. | Preservation of sensitive biological samples by vitrification |
US6444246B1 (en) | 1997-12-16 | 2002-09-03 | Mccormick & Company, Inc. | Cake-resistant, hygroscopically sensitive materials and process for producing the same |
US6352722B1 (en) | 1997-12-23 | 2002-03-05 | Quadrant Holdings Cambridge Limited | Derivatized carbohydrates, compositions comprised thereof and methods of use thereof |
WO1999055310A1 (en) | 1998-04-27 | 1999-11-04 | Altus Biologics Inc. | Stabilized protein crystals, formulations containing them and methods of making them |
US6919446B1 (en) | 1998-01-20 | 2005-07-19 | Grain Processing Corp. | Reduced malto-oligosaccharides |
CA2318604C (en) | 1998-01-20 | 2007-04-10 | Grain Processing Corporation | Reduced malto-oligosaccharides |
ES2248902T3 (en) * | 1998-05-06 | 2006-03-16 | Societe Imagene | LONG-TERM CONSERVATION PROCEDURE OF DNA MOLECULES AND PACKING FOR CARRYING OUT. |
US6306345B1 (en) | 1998-05-06 | 2001-10-23 | Universal Preservation Technologies, Inc. | Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures |
AU762967B2 (en) * | 1998-05-13 | 2003-07-10 | Novozymes A/S | Methods for using dehydrogenases in baking |
EP1027886B1 (en) | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
US6692695B1 (en) | 1999-05-06 | 2004-02-17 | Quadrant Drug Delivery Limited | Industrial scale barrier technology for preservation of sensitive biological materials |
WO2000075281A2 (en) * | 1999-06-09 | 2000-12-14 | University Technology Corporation | Supercritical fluid-assisted nebulization and bubble drying |
NL1012300C2 (en) | 1999-06-11 | 2000-12-12 | Rijksuniversiteit | Stabilizer for pharmaceuticals. |
US6380379B1 (en) | 1999-08-20 | 2002-04-30 | Grain Processing Corporation | Derivatized reduced malto-oligosaccharides |
EP1141193A1 (en) | 1999-10-20 | 2001-10-10 | Grain Processing Corporation | Reduced malto-oligosaccharide cleansing compositions |
WO2001028325A2 (en) | 1999-10-20 | 2001-04-26 | Grain Processing Corporation | Compositions including reduced malto-oligosaccharide preserving agents |
US6890896B1 (en) * | 1999-11-18 | 2005-05-10 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
CA2389429C (en) | 1999-11-18 | 2012-05-29 | Victor E. Shashoua | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
PT2382970E (en) † | 2000-04-10 | 2013-02-18 | Teva Pharma | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US8404217B2 (en) * | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
AU6124601A (en) | 2000-05-10 | 2001-11-20 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
CA2406939A1 (en) | 2000-05-26 | 2001-12-06 | Invitrogen Corporation | Thermostable reverse transcriptases and uses thereof |
US7575761B2 (en) * | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
GB0017999D0 (en) * | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
US20020106368A1 (en) * | 2000-07-28 | 2002-08-08 | Adrian Bot | Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same |
DE50012114D1 (en) | 2000-09-05 | 2006-04-13 | Zeltz Patrick | Method for the specific determination of DNA sequences by means of parallel amplification |
US6537666B1 (en) | 2000-10-23 | 2003-03-25 | Universal Preservation Technologies, Inc. | Methods of forming a humidity barrier for the ambient temperature preservation of sensitive biologicals |
GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
AU2002248192A1 (en) * | 2000-12-15 | 2002-08-12 | Stratagene | Room temperature stable competent cells |
US6623762B2 (en) | 2001-02-16 | 2003-09-23 | Cambridge Biostability Ltd. | Composition and method for controlled release injections |
EP1401862A4 (en) * | 2001-05-17 | 2004-12-15 | Ceremedix Inc | Peptide compounds for counteracting reactive oxygen species and free radicals |
AU2002331847A1 (en) * | 2001-09-14 | 2003-04-01 | Invitrogen Corporation | Composition for stabilizing biological materials |
KR100958235B1 (en) | 2001-12-19 | 2010-05-17 | 노바르티스 아게 | Pulmonary delivery of aminoglycosides |
UA79281C2 (en) * | 2002-04-03 | 2007-06-11 | Solvay Pharm Bv | Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof |
JP4491241B2 (en) * | 2002-04-03 | 2010-06-30 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Stabilized natural cannabinoid formulations |
US7135180B2 (en) * | 2002-04-11 | 2006-11-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
DE10234165B4 (en) * | 2002-07-26 | 2008-01-03 | Advanced Micro Devices, Inc., Sunnyvale | A method of filling a trench formed in a substrate with an insulating material |
WO2004024749A2 (en) | 2002-09-13 | 2004-03-25 | Invitrogen Corporation | Thermostable reverse transcriptases and uses thereof |
US6927062B2 (en) * | 2002-11-25 | 2005-08-09 | Agdia, Inc. | Controls and standards for assays and method for manufacture thereof |
US20060099567A1 (en) * | 2004-04-08 | 2006-05-11 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
RU2007106714A (en) * | 2004-07-26 | 2008-09-10 | Байер Шеринг Фарма Аг (De) | TREATMENT OF PULMONARY HYPERTENSION BY INHALATION OF ILOPROSTAT WITH A MICROPARTICLES PREPARATION |
US20070031342A1 (en) * | 2005-06-22 | 2007-02-08 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
CA2663440C (en) * | 2006-09-18 | 2014-07-08 | Ge Healthcare Bio-Sciences Corp. | Preparation of glassified biological reagents |
DE102006056790B3 (en) * | 2006-12-01 | 2008-01-17 | IfP Privates Institut für Produktqualität GmbH | Kit for carrying out a polymerase chain reaction comprises reaction vessels loaded by drying aqueous solutions of the reagents in the presence of trehalose alone |
US7738094B2 (en) | 2007-01-26 | 2010-06-15 | Becton, Dickinson And Company | Method, system, and compositions for cell counting and analysis |
US7816135B2 (en) | 2007-07-05 | 2010-10-19 | Becton, Dickinson And Company | Method of analyzing lymphocytes |
WO2010044365A1 (en) * | 2008-10-17 | 2010-04-22 | 国立大学法人東京海洋大学 | Reagent kit for measuring freshness |
CA2688174C (en) | 2008-12-19 | 2018-08-07 | F. Hoffmann-La Roche Ag | Dry composition of reaction compounds with stabilized polymerase |
JP5721704B2 (en) | 2009-06-12 | 2015-05-20 | マイクロニクス, インコーポレイテッド | Rehydratable matrix for dry storage of TAQ polymerase in microfluidic devices |
CN102803507B (en) | 2009-06-12 | 2016-05-25 | 精密公司 | The composition and the method that store in the dehydration of plate reactant for microfluidic device |
CA2785913C (en) * | 2009-12-29 | 2019-05-21 | Ge Healthcare Bio-Sciences Corp. | Improvements to nucleic acid elution |
SG10201908916UA (en) | 2010-04-27 | 2019-11-28 | Scil Tech Gmbh | Stable MIA/CD-RAP formulations |
US9808030B2 (en) | 2011-02-11 | 2017-11-07 | Grain Processing Corporation | Salt composition |
EP2748874A4 (en) | 2011-08-26 | 2015-07-29 | Aviana Molecular Technologies Llc | Biocoated piezoelectric biosensor platform for point-of-care diagnostic use |
AR093297A1 (en) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND |
WO2014068029A1 (en) | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
EP3008177B1 (en) * | 2013-06-11 | 2020-06-03 | Biocartis NV | Biomolecule drying process for long-term storage |
MX2016002177A (en) | 2013-08-30 | 2016-06-28 | Takeda Gmbh | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics. |
CN106164261A (en) | 2014-01-22 | 2016-11-23 | 生命技术公司 | It is applicable to the novel reverse transcriptase of high temperature nucleic acid synthesis |
AR100268A1 (en) | 2014-05-07 | 2016-09-21 | Takeda Gmbh | LIQUID FORMULATION INCLUDING GM-CSF NEUTRALIZING COMPOUND |
Citations (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE159826C (en) * | ||||
US125714A (en) * | 1872-04-16 | Improvement in medical compounds or phosphated candies | ||
US586504A (en) * | 1897-07-13 | Otto marcsch | ||
US1855591A (en) | 1926-02-03 | 1932-04-26 | Wallerstein Co Inc | Invertase preparation and method of making the same |
US2457036A (en) | 1946-04-10 | 1948-12-21 | Albert A Epstein | Coffee concentrate and the process of producing it |
US2648609A (en) * | 1949-01-21 | 1953-08-11 | Wisconsin Alumni Res Found | Method of applying coatings to edible tablets or the like |
US3300474A (en) * | 1964-02-12 | 1967-01-24 | Pharmacia Ab | Sucrose ether copolymerizates |
US3413198A (en) * | 1966-06-30 | 1968-11-26 | Calbiochem | Reagents and method for assaying biological samples |
US3456050A (en) * | 1965-01-13 | 1969-07-15 | Boehringer & Soehne Gmbh | Dragee preparation |
US3480468A (en) * | 1965-02-12 | 1969-11-25 | Farmaceutici Italia | Process of preparing pharmaceutical tablet with orange-peel-like protective sugar coating |
US3554767A (en) * | 1964-04-23 | 1971-01-12 | Merck Ag E | Coated confectionery |
US3694547A (en) * | 1970-11-10 | 1972-09-26 | Lever Brothers Ltd | Anti-dandruff hair preparation |
US4157386A (en) * | 1978-05-18 | 1979-06-05 | Rochelle Paul J | Soft, chewable lozenge forming a sticky coating on teeth when combined with saliva in the mouth which is removable only by brushing |
JPS5597096A (en) | 1979-01-12 | 1980-07-23 | Nec Corp | High-speed mos driving circuit |
US4372942A (en) * | 1981-08-13 | 1983-02-08 | Beecham Inc. | Candy base and liquid center hard candy made therefrom |
US4423086A (en) * | 1979-10-17 | 1983-12-27 | Roquette Freres | Process for hard coating with sorbitol and products obtained thereby |
GB2126588A (en) | 1982-08-31 | 1984-03-28 | Asahi Chemical Ind | A method for stabilizing tumor necrosis factor and a stable aqueous solution or powder containing the same |
EP0111216A2 (en) | 1980-03-31 | 1984-06-20 | Takeda Chemical Industries, Ltd. | Method for enzyme immunoassay and peptide-enzyme conjugate, its lyophilizate, antibody and kit therefor |
US4462982A (en) * | 1981-10-05 | 1984-07-31 | Tanabe Seiyaku Co., Ltd. | Microcapsules and method of preparing same |
EP0140489A1 (en) | 1983-08-05 | 1985-05-08 | Wako Pure Chemical Industries, Ltd. | Method for stabilizing immunologically active substances immobilized on an insoluble carrier and their use in the preparation of reagents for measuring physiologically active substances |
US4551329A (en) * | 1984-01-20 | 1985-11-05 | Joan Harris | Oral medicament lollipop |
WO1986000336A1 (en) * | 1984-06-25 | 1986-01-16 | Suomen Sokeri Oy | A stable glucose isomerase concentrate and a process for the preparation thereof |
US4587267A (en) * | 1983-09-15 | 1986-05-06 | Standard Telephones And Cables, Plc | Controlled release system |
WO1986004095A1 (en) | 1985-01-11 | 1986-07-17 | Unilever Nv | Preparation of reagents |
WO1987000196A1 (en) | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
EP0223221A2 (en) * | 1985-11-21 | 1987-05-27 | Roche Diagnostics GmbH | Water soluble, stabilized peroxidase derivatives, process for their preparation and use in the determination of hydrogen peroxide |
WO1987005300A2 (en) | 1986-02-28 | 1987-09-11 | Biocompatibles Limited | Protein preservation |
EP0244771A2 (en) * | 1986-05-02 | 1987-11-11 | Roche Diagnostics GmbH | Stabilized soluble-dependent nitrate reductase, method for its production and its use |
EP0252750A1 (en) * | 1986-07-10 | 1988-01-13 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Composition and analytical element having stabilized peroxidase |
US4741872A (en) * | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
US4743554A (en) * | 1981-09-08 | 1988-05-10 | Boothroyd John C | Recombinant DNA expression vector encoding for foot and mouth disease virus proteins |
US4749575A (en) * | 1983-10-03 | 1988-06-07 | Bio-Dar Ltd. | Microencapsulated medicament in sweet matrix |
US4753790A (en) * | 1986-12-16 | 1988-06-28 | Warner-Lambert Company | Sorbitol coated comestible and method of preparation |
US4762719A (en) * | 1986-08-07 | 1988-08-09 | Mark Forester | Powder filled cough product |
EP0297887A1 (en) | 1987-06-29 | 1989-01-04 | Quadrant Bioresources Limited | Food process |
US4824938A (en) * | 1984-06-06 | 1989-04-25 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Water-soluble dry solid containing proteinaceous bioactive substance |
US4847090A (en) * | 1986-11-07 | 1989-07-11 | Warner-Lambert Company | Confection product and method for making same |
US4849225A (en) * | 1986-07-10 | 1989-07-18 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Process to prepare solid products containing oil-soluble substance |
WO1989006542A1 (en) | 1988-01-21 | 1989-07-27 | Quadrant Bioresources Limited | Preservation of viruses |
US4863865A (en) * | 1983-08-26 | 1989-09-05 | Felix Franks | Preservation by cold storage |
US4873085A (en) * | 1987-04-20 | 1989-10-10 | Fuisz Pharmaceutical Ltd. | Spun fibrous cosmetic and method of use |
US4898781A (en) * | 1986-11-07 | 1990-02-06 | Showa Denko K.K. | Water-soluble microcapsules |
WO1990005182A1 (en) | 1988-11-11 | 1990-05-17 | Cranfield Biotechnology Ltd. | Enzyme stabilisation |
US4963359A (en) * | 1989-01-30 | 1990-10-16 | Plough, Inc. | Non-cariogenic confections |
US4985252A (en) * | 1987-04-07 | 1991-01-15 | R. I. Ph. Recherche Informatique Et Pharmacie (S.A.R.L.) | Medication, dietetic product and hygienic product in the form of a powered composition obtained by adsorption of active ingredients on a rapidly dissolving sugar and process for obtaining said composition |
US4997654A (en) * | 1989-08-14 | 1991-03-05 | Warner-Lambert Company | Method for increasing salivation for xerostomia patients |
US5051261A (en) * | 1987-11-24 | 1991-09-24 | Fmc Corporation | Method for preparing a solid sustained release form of a functionally active composition |
US5120643A (en) * | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
EP0520748A1 (en) | 1991-06-26 | 1992-12-30 | Pafra Limited | Storage of materials |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4594380A (en) * | 1985-05-01 | 1986-06-10 | At&T Bell Laboratories | Elastomeric controlled release formulation and article comprising same |
GB8517663D0 (en) * | 1985-07-12 | 1985-09-18 | Living Images Ltd | Display unit |
CH674370A5 (en) * | 1987-03-27 | 1990-05-31 | Pier Luigi Prof Dr Luisi | |
JP3146400B2 (en) * | 1993-06-24 | 2001-03-12 | 日清紡績株式会社 | Cable connection method for drum brake |
-
1989
- 1989-02-16 GB GB898903593A patent/GB8903593D0/en active Pending
-
1990
- 1990-02-09 AU AU49244/90A patent/AU622978B2/en not_active Expired
- 1990-02-12 US US07/479,939 patent/US5098893A/en not_active Ceased
- 1990-02-14 DK DK90301561.8T patent/DK0383569T3/en active
- 1990-02-14 EP EP90301561A patent/EP0383569B1/en not_active Revoked
- 1990-02-14 CA CA002010058A patent/CA2010058C/en not_active Expired - Lifetime
- 1990-02-14 DE DE69008891T patent/DE69008891T2/en not_active Revoked
- 1990-02-16 JP JP2037115A patent/JP3068836B2/en not_active Expired - Lifetime
-
1999
- 1999-03-17 US US09/270,791 patent/USRE37872E1/en not_active Expired - Lifetime
Patent Citations (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US125714A (en) * | 1872-04-16 | Improvement in medical compounds or phosphated candies | ||
US586504A (en) * | 1897-07-13 | Otto marcsch | ||
DE159826C (en) * | ||||
US1855591A (en) | 1926-02-03 | 1932-04-26 | Wallerstein Co Inc | Invertase preparation and method of making the same |
US2457036A (en) | 1946-04-10 | 1948-12-21 | Albert A Epstein | Coffee concentrate and the process of producing it |
US2648609A (en) * | 1949-01-21 | 1953-08-11 | Wisconsin Alumni Res Found | Method of applying coatings to edible tablets or the like |
US3300474A (en) * | 1964-02-12 | 1967-01-24 | Pharmacia Ab | Sucrose ether copolymerizates |
US3554767A (en) * | 1964-04-23 | 1971-01-12 | Merck Ag E | Coated confectionery |
US3456050A (en) * | 1965-01-13 | 1969-07-15 | Boehringer & Soehne Gmbh | Dragee preparation |
US3480468A (en) * | 1965-02-12 | 1969-11-25 | Farmaceutici Italia | Process of preparing pharmaceutical tablet with orange-peel-like protective sugar coating |
US3413198A (en) * | 1966-06-30 | 1968-11-26 | Calbiochem | Reagents and method for assaying biological samples |
US3694547A (en) * | 1970-11-10 | 1972-09-26 | Lever Brothers Ltd | Anti-dandruff hair preparation |
US4157386A (en) * | 1978-05-18 | 1979-06-05 | Rochelle Paul J | Soft, chewable lozenge forming a sticky coating on teeth when combined with saliva in the mouth which is removable only by brushing |
JPS5597096A (en) | 1979-01-12 | 1980-07-23 | Nec Corp | High-speed mos driving circuit |
US4423086A (en) * | 1979-10-17 | 1983-12-27 | Roquette Freres | Process for hard coating with sorbitol and products obtained thereby |
EP0111216A2 (en) | 1980-03-31 | 1984-06-20 | Takeda Chemical Industries, Ltd. | Method for enzyme immunoassay and peptide-enzyme conjugate, its lyophilizate, antibody and kit therefor |
US4372942A (en) * | 1981-08-13 | 1983-02-08 | Beecham Inc. | Candy base and liquid center hard candy made therefrom |
US4743554A (en) * | 1981-09-08 | 1988-05-10 | Boothroyd John C | Recombinant DNA expression vector encoding for foot and mouth disease virus proteins |
US4462982A (en) * | 1981-10-05 | 1984-07-31 | Tanabe Seiyaku Co., Ltd. | Microcapsules and method of preparing same |
GB2126588A (en) | 1982-08-31 | 1984-03-28 | Asahi Chemical Ind | A method for stabilizing tumor necrosis factor and a stable aqueous solution or powder containing the same |
EP0140489A1 (en) | 1983-08-05 | 1985-05-08 | Wako Pure Chemical Industries, Ltd. | Method for stabilizing immunologically active substances immobilized on an insoluble carrier and their use in the preparation of reagents for measuring physiologically active substances |
US4863865A (en) * | 1983-08-26 | 1989-09-05 | Felix Franks | Preservation by cold storage |
US4587267A (en) * | 1983-09-15 | 1986-05-06 | Standard Telephones And Cables, Plc | Controlled release system |
US4749575A (en) * | 1983-10-03 | 1988-06-07 | Bio-Dar Ltd. | Microencapsulated medicament in sweet matrix |
US4551329A (en) * | 1984-01-20 | 1985-11-05 | Joan Harris | Oral medicament lollipop |
US4824938A (en) * | 1984-06-06 | 1989-04-25 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Water-soluble dry solid containing proteinaceous bioactive substance |
WO1986000336A1 (en) * | 1984-06-25 | 1986-01-16 | Suomen Sokeri Oy | A stable glucose isomerase concentrate and a process for the preparation thereof |
WO1986004095A1 (en) | 1985-01-11 | 1986-07-17 | Unilever Nv | Preparation of reagents |
US4891319A (en) * | 1985-07-09 | 1990-01-02 | Quadrant Bioresources Limited | Protection of proteins and the like |
EP0229810A1 (en) | 1985-07-09 | 1987-07-29 | Quadrant Bioresources Ltd | Protection of proteins and the like. |
WO1987000196A1 (en) | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
EP0223221A2 (en) * | 1985-11-21 | 1987-05-27 | Roche Diagnostics GmbH | Water soluble, stabilized peroxidase derivatives, process for their preparation and use in the determination of hydrogen peroxide |
US4910135A (en) * | 1985-11-21 | 1990-03-20 | Boehringer Mannheim Gmbh | Water-soluble peroxidase derivatives |
WO1987005300A2 (en) | 1986-02-28 | 1987-09-11 | Biocompatibles Limited | Protein preservation |
EP0244771A2 (en) * | 1986-05-02 | 1987-11-11 | Roche Diagnostics GmbH | Stabilized soluble-dependent nitrate reductase, method for its production and its use |
US4741872A (en) * | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
EP0252750A1 (en) * | 1986-07-10 | 1988-01-13 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Composition and analytical element having stabilized peroxidase |
US4849225A (en) * | 1986-07-10 | 1989-07-18 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Process to prepare solid products containing oil-soluble substance |
US4762719A (en) * | 1986-08-07 | 1988-08-09 | Mark Forester | Powder filled cough product |
US4847090A (en) * | 1986-11-07 | 1989-07-11 | Warner-Lambert Company | Confection product and method for making same |
US4898781A (en) * | 1986-11-07 | 1990-02-06 | Showa Denko K.K. | Water-soluble microcapsules |
US4753790A (en) * | 1986-12-16 | 1988-06-28 | Warner-Lambert Company | Sorbitol coated comestible and method of preparation |
US4985252A (en) * | 1987-04-07 | 1991-01-15 | R. I. Ph. Recherche Informatique Et Pharmacie (S.A.R.L.) | Medication, dietetic product and hygienic product in the form of a powered composition obtained by adsorption of active ingredients on a rapidly dissolving sugar and process for obtaining said composition |
US4873085A (en) * | 1987-04-20 | 1989-10-10 | Fuisz Pharmaceutical Ltd. | Spun fibrous cosmetic and method of use |
EP0297887A1 (en) | 1987-06-29 | 1989-01-04 | Quadrant Bioresources Limited | Food process |
US5120643A (en) * | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US5051261A (en) * | 1987-11-24 | 1991-09-24 | Fmc Corporation | Method for preparing a solid sustained release form of a functionally active composition |
WO1989006542A1 (en) | 1988-01-21 | 1989-07-27 | Quadrant Bioresources Limited | Preservation of viruses |
WO1990005182A1 (en) | 1988-11-11 | 1990-05-17 | Cranfield Biotechnology Ltd. | Enzyme stabilisation |
US4963359A (en) * | 1989-01-30 | 1990-10-16 | Plough, Inc. | Non-cariogenic confections |
US4997654A (en) * | 1989-08-14 | 1991-03-05 | Warner-Lambert Company | Method for increasing salivation for xerostomia patients |
EP0520748A1 (en) | 1991-06-26 | 1992-12-30 | Pafra Limited | Storage of materials |
Non-Patent Citations (68)
Title |
---|
"The Journal of Physical Chemistry," vol. 78, No. 28, 1974; Dependence of the Glass Transition Temperature on Heating and Cooling Rate, pp. 2673-2677. |
"The Spray Drying of Enzyme Rennin", Vipin Dhirajlal Shah, University Microfilms, Inc., Ann Arbor Michigan (1963). |
A Polymer Physico-Chemical Approach to the Study of Commercial Starch Hydrolysis Products (SHPs), Harry Levine and Louise Slade, Carbohydrate Polymers, 6 pp. 213-244 (1986). |
Analects(R), Promotional Lecture (Not dated-1992 or later). |
Analects®, Promotional Lecture (Not dated—1992 or later). |
Another View of Trehalose for Drying and Stabilizing Biological Materials, Levine and Slade, BioPharm, 1992. |
BioPharm, Roser, Biopharm, pp. 49-53, Sep. 1991. |
Clas et al., Differential Scanning Calorimentry: Applications in Drug Development,; Research Focus/Reviews vol. 2, No. 8 Aug. 1999, pp. 311-320. |
Dec. 3, 1999 letter from Eric Potter Clarkson to EPO re: Opposition to European patent application No. 90301561.8 (0383569). |
Declaration under 37 CFR 1.132 re: Franks et al. U.S. patent application Ser. No. 08/241,457; filed May 11, 1994; for storage of materials dated Feb. 23, 1996. |
Developments in Biological Standardization, Pikal and Sah International Symposium on Biological Product Freeze-Drying and Formulation Bethesda, USA 74 pp. 165-170 (1991). |
Dielectric Studies of Protein Hydration and Hydration-induced Flexibility, Bone and Pethig, J. Mol. Biol., 181 pp. 323-326, (1985). |
Document in No. 92 305 769.9-Communication/Minutes (Annex) dated Jul. 17, 1998. |
Fax from Eric Potter Clarkson to EPO dated Oct. 15, 1999 re: Further Submissions of Novo Nordisk (Opponent 2). |
Green and Angell, J. Phys. Chem, 89, 2880 (1989). |
Green et al., "The Journal of Physical Chemistry," Phase Relations and Vitrifrication in Saccharide-Water Solutions and the Trehalose Anomaly vol. 93, No. 8, 1989 pp. 2880-2882. |
Hatley et al, Biotechnology & Applied Biochemistry. vol. 11, pp. 367-370, 1989.* * |
Hatley et al, Process Biochemistry. pp. 169-172, Dec. 1987.* * |
Hydration-induced Conformational and Flexibility Changes of Lysozyme at Low Water Content, P.L. Poole and J.L. Finney, Int J. Biol. Macromol., 5 pp. 308-310 (1983). |
Japanese patent publication Sho 60-244288 (1985-244288) 1985 (translation). |
Labrude et al., "Journal of Pharmaceutical Sciences; vol. 78, No. 3, Mar. 1989"; pp. 223-229. |
Labrude et al., s.t.p. pharma, Jun. 1988 No. 6; pp. 472-480. |
Loss of Structure in Freeze-dried Carbohydrates Solutions: Effect of Temperature, Moisture Content and Composition, Spyros Tsourouflis, James M. Flink, and Marcus Karel, J Sci Fd-Agric 27, pp. 509-519 (1976). |
Lyophilization of Biotechnology Products, Arno T. P. Skrabanaja, Andre L. J. De Meere, Rein A. De Ruiter, and Piet J.M. Van Den Detelaar, PDA Journal, 48-6 pp. 311-317 (1994). |
Mar. 6, 2000 letter/fax from Mewburn Ellis to EPO. |
Modes of Stabilization of a Protein by Organic Solutes during Desiccation; John F. Carpenter and John H. Crowe, Department of Zoology, University of California, Davis, California.Cryobiology 25 pp. 459-470 (1988). |
Nov. 1, 1999 fax from Simmons & Simmons, containing claim form and draft amended pleadings. |
Nov. 29, 1999 letter from Mewburn Ellis to EPO. |
Oct. 14, 1999 letter from Mewburn Ellis to EPO. |
Oct. 26, 1999 letter/fax from Mewburn Ellis to EPO containing; letter dated Oct. 15, 1999 to EPO from Akzo Nobel. |
Opinion in Inhale v. Quadrant, Case No. HC 1999 No. 04555 (Jun. 20, 2001). |
Opposition by Quardant to Inhale EP 0,383,569; Declaration by Nicholas David Osborne (Unsigned; Sep. 1999). |
Opposition by Quardant to Inhale EP 0,383,569; Declaration by Trevor George Gard (Unsigned; Sep. 1999). |
Permazyme Tehcnology, Permazyme leaflet (not dated). |
Physical Characterization of Spray Dried Sugars Suitable A Carriers in Inhalation Systems, Venkatesh Naini, Peter R. Byron and Elaine M. Phillips, Aerosol Research Group, Poster at Tenth annual AAPS, Miami, Fl-PT6180 (not dated). |
Polinsky et al, Proc. Natl. Acad. Sci. USA. vol. 72, No. 9., pp. 3310-3314, 1875 .* * |
Preservation of the Enzymatic Activity of Rennin during Spray Drying and During Storage, and the Effect of Sugars and Certain Other Additives, M. J. van de Beek and S. Y. Gerlsma, Neth Mild Dairy J. 23 pp. 46-5 (1969). |
Principles of "Cryostabilization" Technology from Structure/Property Relationships of Carbohydrate/Water systems-A Review, Harry Levine and Louise Slade, Nabisco Brands, inc., Corporate Technology Group.Cryoletters 9 pp. 21-63 (1988). |
Production of Trehalose Dried Eggs, Quandrant Experimental Data (not dated). |
Protein Hydration and Enzyme Activity: The Role of Hydration-Induced Conformation and Dynamic changes in the Activity of Lysozyme, J.L. Finney and P.L. Poole, Comments Mol Cell Biophys, 2 pp. 129-151 (1984). |
Psychrometric Chart (not dated). |
Pure and Applied Chemistry, vol. 60, 1841-1864, Slade and Levine. "Non-Equilibrium Behavior of Small Carbohydrate Water Systems".* * |
Ready-To-To(TM) DNA Labeling Kit, Promotional Lecture (Not dated). |
Ready-To-To(TM) Kits for a broad range of Techniques in Molecular Biology, Designed for results-mot surprises, Promotional Lecture (not dated). |
Ready-To-To™ DNA Labeling Kit, Promotional Lecture (Not dated). |
Ready-To-To™ Kits for a broad range of Techniques in Molecular Biology, Designed for results—mot surprises, Promotional Lecture (not dated). |
Roos-Carbohydrate Research, 238, 39-48 (1993). |
Sep. 13, 1999 letter from Gill Jennings & Every to EPO. |
Sep. 20, 1999 Letter from Gill Jennings & Every to EPO. |
Sequential Hydration of a Dry Globular Protein, P.L. Poole and J.L. Finney, Biopolymers, 22 pp. 255-260 (1983). |
Slade et al, "Non-Equilbrium Behavious of Small Carbohydrate Water Systems." Pure and Applied Chem. vol. 60, No. 12, pp. 1841-1864, 1988.* * |
Some Physico-Chemical Properties of Lactose, B. L. Herrington, J Dairy Science, 17, pp. 501-519, (1934). |
Sperling, Introduction to Physical Polymer Science. New York: John Wiley & Sons pp. 224-295, 1986.* * |
Stabilization of Phosphofructokinase during Air-Drying with Sugars and Sugar/Transition Metal Mixtures, John f. Carpenter, Beth Martin, Lois M. Crowe, and John H. Crowe, Cryobiology, 24 pp. 455-464 (1987). |
Structural Stability of Intermediate Moisture Foods-A New Understanding, Louise Slade and H. Levine, Food Structure, its Creation and Evaluation, Blanshard and Mitchell, pp. 115-180 (1988). |
Structure and Structure Transitions in Dried Carbohydrate Materials, James M. Flink, Physical Properties of Foods, pp. 473-521 (1983). |
Supplemental Amendment re: Franks et al. U.S. patent application Ser. No. 08/241,457; filed May 11, 1994; for storage of materials dated Apr. 22, 1996. |
The Condensed Chemical Dictionary, Seventh Edition, Arthur and Elizabeth Rose, Reinhold Publishing Corporation, p. 448 (1961). |
The Crystalisation of Hydrates From Amorphous Carbohydrates, Barry J. Aldous, Anthony D. Auffret, and Felix Franks, Cryo-Letters 16 pp. 181-186 (1995). |
The Effect of Sugars on the Thermal Denatation of Lysozyme H7H.Uedaira.Bull chem Soc 53 2451 (1980). |
The Glassy State and Survival of Anhydrous Biological Systems, Michael J. Burke, pp. 358-363, (1986) in Membranes, Metabolism, and Dry Organisms, A.C. Leopold, ed. |
The Glassy State in Certin Sugar-Containing Food Products, G.W. White and S. H. Cakebread, J Food Technol. 1, pp. 73-82 (1966). |
The Nature of the Glassy State and the Behavior of Liquids at Low Temperatures, Kauzmann Chem Rev. 43, pp. 219-227 (1948). |
The New Encyclopedia Britannica, vol. 16, Encyclopedia Britannica, Inc., pp. 476-479 (1985). |
Thermostability of Enzyme in the Three-dimensional Network of Polysaccharide Chains, Z. Schneider, A. Stroinski and J. Pawelkiewiz, Bulletin de L'Acad. Polonnaise des Sciences XV1,4, pp. 203 and 204 (1968). |
Use of Lyoprotectants in the Freeze-Drying of a Model Protein, Ribonuclease, Michael W. Townsend and Patrick P. DeLuca, Journal of Parenteral Science & Technology, 42 pp. 190-199 (1988). |
Vo. 41. No. 9, 1968; "Glass Transition in Dehydrated Amorphous Solid", Bull. Chem. Soc. Japan, p. 2322. |
Walter Relations of Foods, R.B. Duckworth, Editor, Academic Press, p. 648 (1975). |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39497E1 (en) * | 1989-02-16 | 2007-02-27 | Nektar Therapeutics | Storage of materials |
USRE38385E1 (en) * | 1989-02-16 | 2004-01-13 | Nektar Therapeutics | Storage of materials |
US7785631B2 (en) | 1994-12-02 | 2010-08-31 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
US7780991B2 (en) | 1994-12-02 | 2010-08-24 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
US7744925B2 (en) | 1994-12-02 | 2010-06-29 | Quadrant Drug Delivery Limited | Solid dose delivery vehicle and methods of making same |
US20050003004A1 (en) * | 2003-05-28 | 2005-01-06 | Nektar Therapeutics | Pharmaceutical formulation comprising a water-insoluble active agent |
US7862834B2 (en) | 2003-05-28 | 2011-01-04 | Novartis Pharma Ag | Pharmaceutical formulation comprising a water-insoluble active agent |
US20110070309A1 (en) * | 2003-05-28 | 2011-03-24 | Novartis Pharma Ag | Pharmaceutical formulation comprising a water-insoluble active agent |
US8668934B2 (en) | 2003-05-28 | 2014-03-11 | Novartis Ag | Pharmaceutical formulation comprising a water-insoluble active agent |
US20050142206A1 (en) * | 2003-07-18 | 2005-06-30 | Larry Brown | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
US20050233945A1 (en) * | 2003-07-18 | 2005-10-20 | Larry Brown | Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation |
US20050170005A1 (en) * | 2003-07-18 | 2005-08-04 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
US20050147687A1 (en) * | 2003-07-18 | 2005-07-07 | Julia Rashba-Step | Methods for fabrication, uses and compositions of small spherical particles of AAT prepared by controlled phase separation |
US20050142201A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for fabrication, uses and compositions of small spherical particles of hGH prepared by controlled phase separation |
US8075919B2 (en) | 2003-07-18 | 2011-12-13 | Baxter International Inc. | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
US20050048127A1 (en) * | 2003-07-22 | 2005-03-03 | Larry Brown | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
US8900856B2 (en) | 2004-04-08 | 2014-12-02 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
US9078426B2 (en) | 2004-04-08 | 2015-07-14 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
US20060039985A1 (en) * | 2004-04-27 | 2006-02-23 | Bennett David B | Methotrexate compositions |
US8333995B2 (en) | 2004-05-12 | 2012-12-18 | Baxter International, Inc. | Protein microspheres having injectable properties at high concentrations |
US7815941B2 (en) | 2004-05-12 | 2010-10-19 | Baxter Healthcare S.A. | Nucleic acid microspheres, production and delivery thereof |
US9339465B2 (en) | 2004-05-12 | 2016-05-17 | Baxter International, Inc. | Nucleic acid microspheres, production and delivery thereof |
US9115357B2 (en) | 2004-05-12 | 2015-08-25 | Baxter International Inc. | Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
US20060018971A1 (en) * | 2004-05-12 | 2006-01-26 | Terrence Scott | Nucleic acid microspheres, production and delivery thereof |
US20060024379A1 (en) * | 2004-05-12 | 2006-02-02 | Larry Brown | Protein microspheres having injectable properties at high concentrations |
US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
US7964574B2 (en) | 2006-08-04 | 2011-06-21 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
US8367427B2 (en) | 2008-08-20 | 2013-02-05 | Baxter International Inc. | Methods of processing compositions containing microparticles |
US20100047903A1 (en) * | 2008-08-20 | 2010-02-25 | Baxter International Inc. | Methods of processing compositions containing microparticles |
US8323615B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing multi-phasic dispersions |
US8323685B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
US10716753B2 (en) | 2009-05-29 | 2020-07-21 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
US9415009B2 (en) | 2009-05-29 | 2016-08-16 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
EP3111926A1 (en) | 2009-05-29 | 2017-01-04 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
US8808713B2 (en) | 2009-05-29 | 2014-08-19 | Pearl Thereapeutics, Inc. | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
US8703806B2 (en) | 2009-05-29 | 2014-04-22 | Pearl Therapeutics, Inc. | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
WO2010138868A2 (en) | 2009-05-29 | 2010-12-02 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems |
US20110132357A1 (en) * | 2009-05-29 | 2011-06-09 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
US20110132356A1 (en) * | 2009-05-29 | 2011-06-09 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting b2 adrenergic receptor agonists and associated methods and systems |
US20110135737A1 (en) * | 2009-05-29 | 2011-06-09 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems |
EP3111927A1 (en) | 2009-05-29 | 2017-01-04 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems |
US8324266B2 (en) | 2009-05-29 | 2012-12-04 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
US9463161B2 (en) | 2009-05-29 | 2016-10-11 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
EP3106149A1 (en) | 2009-05-29 | 2016-12-21 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems |
US20110023876A1 (en) * | 2009-05-29 | 2011-02-03 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US9999217B2 (en) | 2010-07-26 | 2018-06-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
US11471468B2 (en) | 2013-03-15 | 2022-10-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
WO2014190204A1 (en) | 2013-05-22 | 2014-11-27 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of three or more active agents |
US10772319B2 (en) | 2014-06-10 | 2020-09-15 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US10064404B2 (en) | 2014-06-10 | 2018-09-04 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US11672247B2 (en) | 2014-06-10 | 2023-06-13 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US10568317B2 (en) | 2015-12-08 | 2020-02-25 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US11116205B2 (en) | 2015-12-08 | 2021-09-14 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US11286526B2 (en) | 2017-05-19 | 2022-03-29 | Gen-Probe Incorporated | Dried compositions containing flap endonuclease |
WO2023283441A1 (en) | 2021-07-09 | 2023-01-12 | Astrazeneca Pharmaceuticals Lp | Compositions, methods and systems for aerosol drug delivery |
EP4197528A1 (en) | 2021-07-09 | 2023-06-21 | AstraZeneca Pharmaceuticals LP | Compositions, methods and systems for aerosol drug delivery |
WO2023119093A1 (en) | 2021-12-20 | 2023-06-29 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery |
WO2023212191A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
Also Published As
Publication number | Publication date |
---|---|
EP0383569A2 (en) | 1990-08-22 |
EP0383569A3 (en) | 1990-11-22 |
DE69008891T2 (en) | 1994-11-03 |
EP0383569B1 (en) | 1994-05-18 |
AU622978B2 (en) | 1992-04-30 |
US5098893A (en) | 1992-03-24 |
DE69008891D1 (en) | 1994-06-23 |
AU4924490A (en) | 1990-08-30 |
CA2010058C (en) | 2007-11-06 |
JP3068836B2 (en) | 2000-07-24 |
GB8903593D0 (en) | 1989-04-05 |
CA2010058A1 (en) | 1990-08-16 |
DK0383569T3 (en) | 1994-09-05 |
JPH02265984A (en) | 1990-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE37872E1 (en) | Storage of materials | |
USRE39497E1 (en) | Storage of materials | |
US6825031B2 (en) | Storage of materials | |
EP0376361B2 (en) | Enzyme Stabilisation | |
US6294365B1 (en) | Method and formulation for stabilization of enzymes | |
EP1303184B1 (en) | Preservation and storage medium for biological materials | |
AU699590B2 (en) | Stabilized enzyme compositions for nucleic acid amplification | |
US4189401A (en) | Method of storing a biological reference control standard and biological reference control standard obtained thereby | |
US3860484A (en) | Enzyme stabilization | |
CA2040815C (en) | Enzyme stabilisation | |
AU2001268057A1 (en) | Preservation and storage medium for biological materials | |
US4931392A (en) | Process for stabilizing kinase | |
US20030091971A1 (en) | Composition for stabilizing biological materials | |
JPH0147999B2 (en) | ||
CN1286725A (en) | Preservation of sensitive biological samples by vitrification | |
US4219645A (en) | Stabilized nicotinamide-adenine dinucleotides and process for their preparation | |
Cenatiempo et al. | Polysome level and stability in stringent E. coli strains under aminoacyl-tRNA deprivation | |
Kaul et al. | Storage stability of enzymes in dry apolar solvent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NEKTAR THERAPEUTICS, CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:INHALE THERAPEUTIC SYSTEMS, INC.;REEL/FRAME:013525/0753 Effective date: 20030113 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: NOVARTIS PHARMA AG,SWITZERLAND Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001 Effective date: 20081231 Owner name: NOVARTIS PHARMA AG, SWITZERLAND Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001 Effective date: 20081231 |